http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : Kang Zhong-Jian (검색결과 3 건)
- 무료
- 기관 내 무료
- 유료
-
Kang Zhong-Jian,Sun Yi-Sen,Liu Jia-Xuan 대한전기학회 2023 Journal of Electrical Engineering & Technology Vol.18 No.2
The existing asynchronous motor parameter identification methods only identify the parameters of the asynchronous motor itself, ignoring the identification of the parameters of the load carried by the asynchronous motor. This paper proposes an integrated parameter identification method of the asynchronous motor that uses the improved PSO (Particle Swarm Optimization, PSO) and considers the load adaptive characteristics. Compared with the traditional method, this method firstly combines the PSO method with Space Disturbance (SD) to form an improved PSO method, which prevents the PSO from falling into a local optimal state and enhances the global optimization ability of the PSO method. Secondly, according to the characteristics of different loads, a load identification strategy is constructed. This strategy can judge the type of load carried by the asynchronous motor, which reduces the optimization exploration space of the PSO algorithm and accelerates the optimization speed of the PSO algorithm. Finally, according to the identified load types, the improved particle swarm optimization algorithm combined with the spatial disturbance is used to realize the integrated identification of the asynchronous motor and the load parameters. The validity of the algorithm is verified by an example, and the factors affecting the identification accuracy are analyzed.
-
Hou-Yang Kang,Li-Juan Lin,Zhi-Jian Song,Jing-Ya Yuan,Mei-Yu Zhong,Hai-Qin Zhang,Xing Fan,Li-Na Sha,Yi Wang,Li-Li Xu,Jian Zeng,Yong-Hong Zhou 한국유전학회 2012 Genes & Genomics Vol.34 No.5
Semi-dwarfism is an agronomically important trait in breeding for resistance to damage by wind and rain (lodging resistance)and for stable high yields. Dwarf Polish wheat (Triticum polonicum L., 2n = 4x = 28, AABB AS304) is a potential donor of dwarfing and other traits for common wheat improvement. A genetic analysis using an F2 population derived from a cross of AS304 and tall cultivar AS302 and derived F2:3 lines indicated that AS304 carries a recessive dwarfing gene, temporarily designated Rht-dp. Molecular markers and bulked segregant analysis were used to characterize and map the gene. Eight polymorphic SSR markers (Xwmc511, Xgwm495, Xgwm 113, Xgwm192, Xgpw7026, Xgpw3017, Xgpw1108 and Xgpw7521) on chromosome arm 4BS and two AFLP markers (M8/E5 and M4/E3) were mapped relative to the dwarfing locus. The closest linked markers, Xgpw3017 and M8/E5 at 0.5 and 3.5 cM, respectively, from Rht-dp will enable its marker assisted transfer to wheat breeding populations. Allelic tests indicated that Rht-dp was allelic to Rht-B1b; hence it may be an alternative allele at the Rht-B1 locus.
-
Jing Li,Jian Kang,Changzheng Wang,Jing Yang,Linda Wang,Ioannis Kottakis,Michael Humphries,Nanshan Zhong,China Omalizumab Study Group 대한천식알레르기학회 2016 Allergy, Asthma & Immunology Research Vol.8 No.4
Purpose: Omalizumab is the preferred add-on therapy for patients with moderate-to-severe persistent allergic asthma and has demonstrated efficacy and safety in various ethnicities. This study evaluated the efficacy and safety of omalizumab in Chinese patients with moderate-to-severe allergic asthma. Methods: This randomized, double-blind, parallel-group, placebo-controlled, phase III study assessed lung function, quality of life, asthma control, and safety of omalizumab after 24-week therapy in Chinese patients (18-75 years of age). Results: A total of 616 patients were randomized (1:1) to omalizumab or placebo. The primary endpoint, least squares mean treatment difference (LSM-TD) in morning peak expiratory flow (PEF) (omalizumab vs placebo), at Weeks >20-24 was 8.85 L/min (Full analysis set; P=0.062). Per-protocol analysis set showed significant improvements with LSM-TD of 11.53 L/min in mean mPEF at Weeks >20-24 (P=0.022). The FEV1 % predicted was significantly improved with omalizumab vs placebo from 8 to 24 weeks (after 24-week treatment: LSM-TD=4.12%; P=0.001). At Week 24, a higher proportion of omalizumab-treated patients achieved clinically relevant improvements in standardized AQLQ (58.2% vs 39.3%; LSM=0.51 vs 0.10; P<0.001) and ACQ (49.5% vs 35.5%; LSM=-0.51 vs -0.34; P=0.002) scores vs placebo. Total and nighttime symptom scores reduced significantly with omalizumab vs placebo (LSM-TD=-0.21, P=0.048 and -0.12, P=0.011, respectively). Although the study was not powered to study differences in exacerbation rates (P=0.097), exacerbations in winter months were less frequent in the omalizumab vs placebo group (2 vs 21). Adverse event and severe adverse event rates were comparable between omalizumab and placebo. Conclusions: Omalizumab improves lung function, quality of life, and asthma control in Chinese patients with moderate-to-severe persistent allergic asthma and has a good safety profile.
연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
